Middle East and Africa Tulathromycin Market Size & Outlook, 2025-2033

Middle East and Africa Tulathromycin Market Size

The Middle East and Africa tulathromycin market size was valued at USD 0.021 billion in 2024 and is projected to grow from USD 0.022 billion in 2025 to reach USD 0.029 billion by 2033, growing at a CAGR of 3.3% during the forecast period (2025–2033).

Bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis is treated with the generic drugs Macrosyn and Increxxa in beef and non-lactating dairy cattle, suckling calves, dairy calves, and veal calves.

In addition, pet owners in the area are starting to pay greater attention to the health and welfare of their animals. They know the significance of giving their dogs the proper care to ensure a high quality of life. Veterinary clinics and other pet healthcare providers play a critical role in educating the public on the value of routine checkups, vaccines, and antibiotics when necessary.

To get more insights about this report Download Free Sample Report

Middle East and Africa Tulathromycin Market Growth Factor

Rising Veterinary Healthcare Awareness

Livestock producers in the Middle East and Africa region increasingly recognize the significance of preventive healthcare measures to ensure the well-being and productivity of their animals. They know that keeping their cattle healthy increases productivity and reduces financial losses. As a result, they are actively looking for ways to shield their animals from illness and treat it, which includes using antibiotics like tulathromycin.

Restraining Factor

Entry of Generic Tulathromycin

Two generic tulathromycin injectable medicines have just received FDA approval in 2021 for the treatment and management of specific diseases in both cattle and swine. Additionally, it's used to treat swine respiratory disease (SRD), which is a condition that affects swine and is brought on by pathogens like Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae.

The approved brand-name drug product Draxxin, first approved in 2005, shares the same active component (tulathromycin) with Macrosyn and Increxxa in the same dose form and concentration. These two generic medications are anticipated to reduce the demand for tulathromycin in the next few years. By consuming some of the demand for the name-brand Draxxin, the demand for generic medicines will increase more quickly.

Market Opportunity

Focus on Animal Welfare

Given the increasing attention paid to animal welfare, the Middle East and African tulathromycin markets have a sizable opportunity. Consumers are looking for products that reflect their ideals and give the ethical treatment of animals more weight. In the veterinary pharmaceutical industry, where customers are looking for antibiotics and other treatments that improve animals’ general health and well-being, this shift in consumer preferences is also present.

Additionally, businesses can participate in transparent and traceable supply chains, disclosing where tulathromycin is sourced and guaranteeing its manufacture complies with stringent animal welfare requirements. This may entail collaborating closely with livestock farmers to ensure cattle are raised in conditions that support their well-being, such as having access to enough space, wholesome food, and veterinary treatment. By exhibiting these initiatives, companies can attract customers who are concerned about the conditions in which animals are raised and look for products that contribute to their well-being.

Regional Analysis

The market share held by MEA is the lowest. The Middle East's economies mostly rely on oil, and freshwater is in short supply.  As a result, people in this area strive to avoid raising cattle and rely heavily on beef imports. On the other hand, most of the countries in the region are Muslim, which lowers the need for related goods and antibiotics like tulathromycin and pig rearing.

On the other hand, it has been discovered that several African nations produce beef and raise dairy cows. However, compared to other areas, adoption is much lower.

Animal Type Insights

The market is segmented into cattle and swine. Cattle dominated the market and is expected to register a CAGR of 3.9% over the forecast period. Tulathromycin treats and prevents bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in cattle. Respiratory disease plays a significant role in weaned calf mortality, and bovine respiratory disease (BRD) morbidity affects survivability and reduces dairy performance later in life.

List of key players in Middle East and Africa Tulathromycin Market

1. Zoetis
2. Zhejiang Genebest Pharmaceutical
3. Wisdom Pharmaceutical
4. Amicogen Biopharm
5. Hubei Honch Pharmaceutical
6. Livzon New North River Pharmaceutical
7. AVF Chemical Industrial
8. Jiangsu Lingyun Pharmaceutical

To get more findings about this report Download Market Share

Recent Developments

• August 2023: Livzon New North River Pharmaceutical announced that its novel tulathromycin product, Tulathromycin Granules for Injection, had won approval from the CFDA.